Publikation

Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors

Wissenschaftlicher Artikel/Review - 01.03.2007

Bereiche
PubMed
DOI

Zitation
Sessa C, Marsoni S, Zanna C, Carminati P, Gatti B, Capri G, Zaniboni A, D'Incalci M, Zucchetti M, Trigo J, Hess D, Malossi A, Rota Caremoli E, Baselga J, Cerny T, Cresta S, Gianni L. Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007; 18:561-8.
Art
Wissenschaftlicher Artikel/Review (Englisch)
Zeitschrift
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007; 18
Veröffentlichungsdatum
01.03.2007
ISSN (Druck)
0923-7534
Seiten
561-8
Kurzbeschreibung/Zielsetzung

BACKGROUND: Gimatecan is an orally bioavailable camptothecin analogue with preclinical findings of promising antitumor activity. A phase I design of concerted dose escalation and dosing duration was implemented to assess the potential schedule dependency of tolerability that emerged from animal studies. PATIENTS AND METHODS: Gimatecan was given daily for five consecutive days per week for 1, 2 or 3 weeks every 28 days. Plasma levels of total gimatecan were measured on the first and the last day of treatment in each schedule. RESULTS: Overall, 108 patients were treated with 0.8-7.2 mg/m(2) of gimatecan per cycle. The main toxicity was myelosuppression with dose-limiting thrombocytopenia. In the 1-, 2- and 3-week schedule, the maximum tolerated doses were 4.5, 5.6 and 6.4 mg/m(2). Diarrhea and asthenia were of low grade and of minor clinical relevance, while the higher incidence of nausea and vomiting in the 1-week schedule required the use of antiemetic prophylaxis. Due to the prolonged half-life (approximately 77 h), the plasma concentration of gimatecan increased from the first to the last day of dosing. Six partial responses were observed. CONCLUSIONS: Tolerability of gimatecan was schedule dependent. Further testing with schedules taking into account its long persistence in human plasma is worthwhile.